Cobimetinib (GDC-0973, XL518) is a potent, selective MEK inhibitor with IC50 of 4.2 nM for MEK1.
Cobimetinib (GDC-0973, XL518) shows excellent selectivity against mTOR, DNA-dependent protein kinase (DNA-PK), and a panel of more than 228 kinases.
Cobimetinib (GDC-0973, XL518) shows strong cellular potency in a broad panel of tumor types, particularly in BRAF or KRAS mutant cancer cell lines, triggers robust apoptosis and tumor growth inhibition in vivo combined with PI3K inhibitor GDC-0941.
